RSPO3 and neoplasm: PTPRK is a recurrent gene fusion with RSPO3, a Wnt pathway potentiator, particularly in serrated adenoma (Sekine et al., 2016), a tumour type associated with a more mesenchymal phenotype (Fessler et al., 2016).